68 Early clinical experience with tobramycin inhalation powder (TIP)  by McKinney, M.L. et al.
S74 5. Microbiology Posters
68 Early clinical experience with tobramycin inhalation powder (TIP)
M.L. McKinney1,2, V. Fauvel1, J.-E´. Marcotte1,2. 1CHU-Sainte Justine, Pediatric
Pulmonology, Montreal, Canada; 2Universite´ de Montre´al, Pediatrics, Montreal,
Canada
Objectives: Chronic treatment with inhaled antibiotics is part of the treatment
regimen for cystic ﬁbrosis patients chronically colonized with Pseudomonas aerug-
inosa. Previously available treatments included nebulized antibiotics, but use of
available preparations could be burdensome for patients and families. Two “new-
generation” formulations recently become available in Canada. We describe early
experiences with Tobramycin Inhalation Powder (TIP, TOBI® Podhaler®) in a large
pediatric CF centre.
Methods: Patients who had initiated therapy with TIP were identiﬁed by retro-
spective chart review and demographic information was recorded (patient age, sex,
CFTR mutation, culture results over 12 months, and treatment before starting TIP).
Patients who ceased using TIP were identiﬁed.
Data: TIP ﬁrst became commercially available in Canada in April 2011. There are
170 patients between the ages of 6−18 years enrolled in the CHU-Sainte Justine
clinic. As of January 2012, 32 patients had started therapy with TIP (mean age:
13.4 years (range 6−18 years, SD = 3.1 years), 14 females/18 males. 22 DF508
homozygous, 7 others with one DF508 allele). All were chronically colonized
with P. aeruginosa; 31 also had other organisms. Before TIP, 12 were treated with
TOBI®, 8 tobramycin, 9 colymycin, 1 tobramycin + colymycin, and 2 untreated.
Three patients stopped therapy: 1 due to poor Podhaler technique, 1 bronchospasm,
and 1 negative cultures for P. aeruginosa for 1 year.
Conclusion: Early clinical experience with TIP in our centre has been positive,
with initiation of therapy in 32 patients to date. Only 3 have stopped therapy, 2 due
to factors associated with TIP.
69 Efﬁcacy on lung function and safety of multiple courses of
tobramycin 300mg/4mL nebuliser solution (Bramitob) in patients
with cystic ﬁbrosis and chronic Pseudomonas aeruginosa
infection: results from a 48-week extension phase
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Objectives: Following an 8-week, open-label, randomized trial in cystic ﬁbrosis
(CF) patients with chronic Pseudomonas aeruginosa (Pa) infection comparing
tobramycin 300mg/4mL nebuliser solution (TNS4; Bramitob®, Chiesi Farmaceu-
tici S.p.A.) vs tobramycin 300mg/5mL (TNS5, Tobi, Novartis Pharmaceuticals),
efﬁcacy and safety of TNS4 were evaluated for an additional 48-week, single-arm
extension (EXT).
Methods: CF pts 6 years having baseline 1-sec forced expiratory volume (FEV1)
40−80% predicted were enrolled in the 8-week study and then received TNS4
for six additional 28-day on/off cycles. TNS4 was administered by PARI LC Plus
nebulizer. FEV1 assessments and monitoring of adverse events and audiometry
were performed.
Results: A total of 209 pts entered and 186 pts completed the EXT. The signiﬁcant
improvement from baseline in FEV1% predicted observed at the end of initial
4-week treatment period (7.0% [95%CI: 5.5; 8.5] for TNS4 and 7.5% [95%CI:
6.0; 9.0] for TNS5) was maintained throughout the EXT. The mean change in
FEV1% predicted between the start and the end of EXT was 1.1% [95%CI: −1.0;
3.2]. TNS4 was well tolerated having no remarkable safety ﬁndings.
Conclusion: The improvement in FEV1 observed during the 8-week phase fol-
lowing treatment with TNS4 was maintained during the additional 48-week study
period. The good safety and tolerability proﬁle of TNS4 was also conﬁrmed.
Supported by: Chiesi Farmaceutici.
70 Comparative research of TOBI and Bramitob in cystic ﬁbrosis (CF)
patients with chronic Pseudomonas aeruginosa (PA) infection in
the Moscow Region
V. Nikonova1, N. Kapranov1. 1Research Center Medical Genetic of Russian
Academy of Science, Moscow, Russian Federation
The inhalation tobramycin preparations TOBI/Bramitob are given to CF patients
with PA infection from 2009 in the Moscow region.
Objective: To compare the efﬁcacy of inhalation tobramycin-TOBI/Bramitob in CF
patients with chronic PA infection.
Material: Inhalations of TOBI/Bramitob were appointed in addition to standard
therapy and other antipseudomonal antibiotics. 28 days of preparations in the dose
of 300mg twice a day and 28 days of wash out period. Microbiological composition
of sputum, the data of FEV1, FVC, nutritional status, number of exacerbations
of bronchopulmonary process that required hospitalization were evaluated after 6
courses of therapy. In total 62 patients, Bramitob group − 33 patients the average
age 11.4(±4.2) years, TOBI group − 29 patients 9.9(±3.9) years.
Results: Eradication in TOBI group − 34.5% vs. 30.3%, in Bramitob group
accordingly. Increase BMI in TOBI group − 0.34(±0.64) kg/m2, Bramitob −
0.28(±0.93) kg/m2. Increase FEV1 TOBI − 5.7% (±17.3), Bramitob 5.2% (±14.9)
and FVC in TOBI group − 4.2% (±15.8), Bramitob − 4.6% (±13.6). Number of
hospitalizations for treatment exacerbations of bronchopulmonary process in TOBI
group were 1.2(±1), Bramitob − 1.3(±1.1).
Conclusion: The results conﬁrm that TOBI and Bramitob are comparable in clinical
and functional efﬁcacy for CF patients with chronic PA infection.
71 Is a once daily dose of 5mg/kg a sensible compromise between
the risks and beneﬁts of intravenous tobramycin?
F.J. Gilchrist1, K.J. Cox1, A.K. Webb1, R.J. Bright-Thomas1, A. Jones1.
1Manchester Adult Cystic Fibrosis Unit, Manchester, United Kingdom
Objectives: Tobramycin exhibits a concentration-dependent bacterial activity but
repeated doses are associated with nephro/ototoxicity. Due to these side effects the
regimen for intravenous (IV) tobramycin at our unit is a once daily 5mg/kg infusion.
Improved bactericidal activity and therapeutic outcomes have been observed in
gram-negative pneumonia when the aminoglycoside peak serum concentration
(PSC) / minimum inhibitory concentration (MIC) ratio is >10. We investigated
if patients on 5mg/kg IV tobramycin achieved this ratio.
Methods: We recruited 20 adults with CF and chronic Pseudomonas aeruginosa
(PA) infection on 5mg/kg (±10%) IV tobramycin for an exacerbation. A peak
tobramycin level was taken and the tobramycin MIC calculated for all PA isolates
cultured from the admission sputum sample.
Results: Thirty ﬁve isolates of PA were cultured from the 20 sputum samples. The
median(IQR) tobramycin MIC was 0.75 (0.5−1.9) mg/L. There was no signiﬁcant
difference between the tobramycin MIC for mucoid and non-mucoid samples
(p = 0.5) or for epidemic and sporadic strains (p = 0.2). The median(IQR) PSC/MIC
ratio was 11.6(5.2–21.6). 13 isolates of PA (from 9 patients) had a PSC/MIC ratio
<10 but 9 of these isolates (from 6 patients) had an MIC 2, so even with 10mg/kg
it is unlikely the PSC/MIC ratio would be >10.
Conclusions: Most patients on 5mg/kg of IV tobramycin achieved a PSC/MIC
ratio >10. Of those that did not, only 3 are likely to have achieved this ratio with a
dose of 10mg/kg. The dosing of IV tobramycin is a balance between the beneﬁt of
increased antimicrobial action and the cost of signiﬁcant side effects. A once daily
dose of 5mg/kg is a possible compromise.
